Calendar

AAR has strong company-reported growth and FY2027 guidance, but the checked sources did not verify positive current-quarter estimate revisions or a revenue-upside signal, and the stock fell sharply into the event with weak close locations; operating momentum alone does not overcome the tape and evidence gaps.

AutoZone has credible upcoming EPS and revenue estimates, positive recent operating momentum, and a modest three-month revenue-estimate increase, but EPS estimates drifted lower and the stock sold off sharply into the event while XLY weakened; the tape does not support an upside-surprise setup.

Thor has a credible consensus EPS and revenue source and some resilient motorized and European demand, but both EPS and revenue estimates were revised lower, management cut full-year EPS guidance, the stock fell sharply into earnings, and XLY was weak; this is a cyclical turnaround watch rather than a pre-earnings surprise setup.

KB Home has a recent built-to-order catalyst, a positive five-session bounce, a strong close location, and above-normal volume, but accessible estimates imply sharply lower year-over-year EPS and revenue, estimate revisions were not available, housing-sector tape was weak, and the latest EPS miss keeps this below the surprise threshold.

Ferguson has solid recent operating execution and credible consensus EPS and revenue estimates, but the accessible sources did not verify positive estimate revisions or a whisper edge, while the stock was in a pronounced decline into earnings; the evidence is insufficient for a surprise-oriented setup.

Post-earnings tone is positive on strong profitability, charter coverage, dividend support, and fleet expansion. However, the exact post-print price reaction and formal analyst revisions are unavailable, while low coverage and loose peers limit confidence. The setup remains a cautious monitoring view rather than a high-conviction momentum call.

The post-earnings company disclosure is strategically positive but financially mixed: Q2 revenue increased and contracted license value expanded, while recognition lag, high operating costs and equity financing remain central concerns. Coverage is thin, social context is unavailable, and no dependable analyst revision or consensus-surprise signal is present. This supports tentative positive monitoring rather than a high-conviction bullish thesis.

Post-earnings sentiment is mixed-to-negative: the pivot improves near-term commercial relevance but raises uncertainty around financing, offtake, dilution, and the timing of carbon capture. The packet does not provide verified analyst revisions or consensus surprise data, so this remains a low-coverage monitoring view rather than a high-conviction call.

The post-earnings company source provides mixed evidence: Q2 revenue and cash were disclosed, commercial performance was broadly in line with recent quarters, and LOTIS-7 enrollment was complete, but substantial FDA concerns remain around LOTIS-5. No reliable post-print price reaction, analyst revisions, target changes, or social-sentiment coverage was available in the packet; missing reaction data is not positive evidence. The peer set contains only broad same-sector, similar-market-cap screens rather than direct operating comparators, so it cannot support standard-conviction valuation work. Low coverage and binary clinical and regulatory risk support a cautious monitoring view. [#SEC-8K-2026-08-13]

The T+3 evidence is constructive but not decisive: the company delivered an EPS and revenue beat, issued concrete Q3 volume guidance, and the stock rose 3.91% the day after the release. Secondary coverage shows some favorable analyst actions, but the packet lacks a complete post-print consensus and revision series. Social coverage is unavailable, and the loose peer set keeps conviction at monitoring level rather than a strong directional call. [#SEC-8K-2026-08-13] ([TipRanks earnings history](https://www.tipranks.com/stocks/figr/earnings))

News flow is sparse and mixed. The official investor-relations source confirms a scheduled Q2 reporting event, not completed earnings results; therefore no earnings surprise, analyst revision, target change or post-print price reaction can be confirmed. The positive deterministic update is treated as a tentative monitoring signal because evidence quality is low and uncertainty is high. [#PR-EARNINGS-2026-08-13]